OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...
EXPANSION ADDS STATE-OF-THE-ART UPSTREAM AND DOWNSTREAM GMP PROCESSING CAPABILITIES TO MEET THE GROWING DEMAND FOR 2,000 LITER SCALE SINGLE USE BIOLOGICS MANUFACTURING. SAN DIEGO, CA / ACCESS Newswire ...
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis ...
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging ...
Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results